| Title: |
Large B-cell lymphoma: The LYSA pragmatic guidelines |
| Authors: |
Sesques, Pierre; Manson, Guillaume; Dubois, Sydney; Gros, Francois Xavier; Brisou, Gabriel; Sarkozy, Clémentine; Bernard, Sophie; Bourbon, Estelle; Fornecker, Luc Matthieu; Durot, Eric; Martin, Laurent; Chassagne-Clément, Catherine; Llamas Gutierrez, Francisco; Syrykh, Charlotte; Delfau-Larue, Marie-Hélène; Kanoun, Salim; Vercellino, Laetitia; Bodet-Milin, Caroline; Bahri, Haifa; Zhang Yin, Jules; Dony, Arthur; Lebras, Laure; Ochmann, Marlène; Baron, Marine; Monjanel, Helène; Le Calloch, Ronan; Claves, Fabien; Kirova, Youlia; Gisselbrecht, Christian; Guidez, Stéphanie; Bossard, Jean Baptiste; Di Blasi, Roberta; Delette, Caroline; Fouillet, Ludovic; Rhomdani, Maryem; Belhadj, Maya; Crochet, Gilles; Amorim, Sandy; Safa, Firas; Drieu La Rochelle, Laurianne; Abraham, Julie; Thieblemont, Catherine; Jardin, Fabrice; Noel, Robin; Bailly, Sébastien; Renaud, Loic; Guillermin, Yann; Delapierre, Baptiste; Choquet, Sylvain; Roulin, Louise; Lamure, Sylvain; Galicier, Lionel; Al Tabaa, Yassine; Soussain, Carole; Guièze, Romain; Houot, Roch; Tessoulin, Benoit |
| Contributors: |
Hospices Civils de Lyon (HCL); Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Pontchaillou; Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC); Université de Rennes (UR)-Établissement Français du Sang Bretagne Rennes (EFS Bretagne - Rennes); Établissement Français du Sang La Plaine Saint-Denis (EFS)-Établissement Français du Sang La Plaine Saint-Denis (EFS)-Institut National de la Santé et de la Recherche Médicale (INSERM); Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND); Université de Rouen Normandie (UNIROUEN); Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM); Institut de Cancérologie de Strasbourg Europe (ICANS); Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037); Université Toulouse III - Paul Sabatier (UT3); Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM); CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Institut Curie Paris; Institut Paoli-Calmettes (IPC); Fédération nationale des Centres de lutte contre le Cancer (FNCLCC); Département d'hématologie Gustave Roussy; Institut Gustave Roussy (IGR); Centre Léon Bérard Lyon; Institut Curie - Saint Cloud (ICSC); Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers (CRCI2NA); Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE); Nantes Université - pôle Santé; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ); None |
| Source: |
ISSN: 0959-8049 ; European Journal of Cancer ; https://univ-rennes.hal.science/hal-05425271 ; European Journal of Cancer, 2026, 232, pp.116070. ⟨10.1016/j.ejca.2025.116070⟩. |
| Publisher Information: |
CCSD; Elsevier |
| Publication Year: |
2026 |
| Collection: |
Université Toulouse III - Paul Sabatier: HAL-UPS |
| Subject Terms: |
Level of evidence; Large B-cell lymphoma; LYSA; Guidelines; [SDV.CAN]Life Sciences [q-bio]/Cancer |
| Description: |
International audience ; The management of large B-cell lymphomas (LBCL) has undergone major changes over the last 5 years. These changes reflect the availability of new therapies (immunotherapies, cell therapies, targeted molecules), but also a better compartmentalization of the entities and their specific clinical characteristics. Numerous first-, second- and third-line therapeutic strategies are available, and each practitioner is committed to selecting the treatment that offers the best balance between efficacy and toxicity. Advances in the understanding of LBCL biology, coupled with improvements in diagnostic and monitoring tools and therapeutic approaches, have significantly enhanced patient outcomes in recent years. In this article, we present a set of pragmatic guidelines developed by the LYSA (Lymphoma Study Association) for the management of LBCL. These guidelines address key aspects of diagnosis, staging, response evaluation, and treatment, integrating the latest evidence from clinical trials, expert consensus, and real-world practice. They aim to provide clinicians with a clear, practical framework to optimize care for patients with LBCL, ensuring that the best available evidence is translated into clinical practice. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/41352004; PUBMED: 41352004 |
| DOI: |
10.1016/j.ejca.2025.116070 |
| Availability: |
https://univ-rennes.hal.science/hal-05425271; https://univ-rennes.hal.science/hal-05425271v1/document; https://univ-rennes.hal.science/hal-05425271v1/file/1-s2.0-S0959804925009566-main%20%281%29.pdf; https://doi.org/10.1016/j.ejca.2025.116070 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/OpenAccess |
| Accession Number: |
edsbas.1D5B80D4 |
| Database: |
BASE |